Harnessing Endogenous Plasticity Rather than Reprogramming of Mature Cells Will Advance Regenerative Medicine, Cancer Treatment and Rejuvenation.

Advances in Induced Pluripotent Stem Cell

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from a somatic cell. The iPSC technology was pioneered by Shinya Yamanaka’s lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes (named Myc, Oct3/4, Sox2 and Klf4) encoding transcription factors could convert somatic cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent." Pluripotent stem cells hold promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.

Translational cell fate reprogramming and regenerative medicine enabled by microphysiological systems.

This review discusses how organoids and OoC-based platforms are being leveraged to study and enhance cell fate reprogramming, repair, and regeneration across multiple tissues and outlines current limitations, including scalability, standardization, and biomaterial constraints.

Protocol For Differentiating Pluripotent Stem Cells Into Primordial Germ Cell-like Cells.

Using human pluripotent stem cell differentiation in vitro has significantly broadened the understanding of lineage specification events that occur during early development in vivo, a period that is extremely challenging to investigate. One of the first embryonic lineages to be specified in the human embryo is the germ cell lineage, marked by the induction of the primordial germ cells (PGCs). The PGCs are the sole founder population of the gametes later in life, and their specification is a critical first step towards the organism's fertility. Here, a robust protocol for generating PGC-like cells (PGCLCs) from human induced pluripotent stem cells (hiPSCs) is described, starting with the initial evaluation of the pluripotent state and cellular characteristics of the hiPSCs to ensure effective PGCLC differentiation. For this, the effects of different cell densities, plate coatings, and hiPSCs used for PGCLC differentiation are discussed. Finally, a workflow for characterization and quantification of hPGCLCs, using immunofluorescence and flow cytometry, is provided. The differentiation protocol focuses on conditions that are easy to establish and test in most laboratories and can be adjusted as necessary. Moreover, this protocol is fast, allowing determination of whether hiPSCs are suitable for PGCLC differentiation. The protocol aims to promote consistency and compatibility in hPGCLC outcomes across different hiPSC lines and culture platforms, ensuring robust yields that support reliable characterization and further optimization of downstream differentiation steps toward successful in vitro gametogenesis in humans.

Modeling myeloid cell development in health and disease using induced pluripotent stem cells

Key applications of iPSC technology in hemato-oncology are summarized, its major advantages and current limitations are discussed, and emerging directions are highlighted, including scalable iPSC-derived blood cell therapies for inherited and acquired bone marrow failure syndromes and leukemia.

Rapid direct neuronal reprogramming of human dental pulp stem cells

Direct neuronal reprogramming offers an alternative to induced pluripotent stem cell-based differentiation by converting somatic cells directly into neurons without passage through pluripotency. However, commonly used fibroblast-based protocols are often slow and inefficient. Here, we evaluated human dental pulp stem cells (DPSCs), which originate from the cranial neural crest and possess intrinsic neurogenic potential, as a developmentally relevant source of induced neurons (iNs). Using an all-in-one lentiviral vector, we converted DPSCs into iNs within 17 days, compared with 28 days for fibroblasts reprogrammed with the same vector, and achieved significantly higher neuronal purity under the respective established protocols. Multi-omic profiling revealed coordinated suppression of mesenchymal and cell-cycle programs and induction of neuronal, synaptic, and metabolic pathways. Single-nucleus RNA sequencing resolved fibroblast-like, transitional, maturing neuronal, GABAergic-like, and alternative fates, while trajectory inference suggested divergent neuronal and non-neuronal conversion paths. Whole-cell recordings showed that a subset of DPSC-iNs developed early neuronal excitability and voltage-gated inward and outward currents. Together, our findings establish DPSCs as an accessible and developmentally relevant source for rapid direct neuronal conversion. This integrated molecular, single-nucleus, and electrophysiological characterization defines the cellular heterogeneity of DPSC-to-neuron reprogramming and provides a framework for protocol refinement and future patient-specific disease modeling.

Ability of conservation embryonic stem cells, umbilical cord blood mesenchymal stem cells as a feeder layer